Moloney Leukemia Virus-Induced Cell Surface Antigen Mimicry by Monoclonal Antibodies

Abstract

We have investigated antigen-independent modulation of immune responses by monoclonal antibodies directed against both viral and nonviral antigens. BALB/c mice were immunized with monoclonal IgM (i.e. Ab1) specific for either Moloney murine leukemia virus-induced cell surface antigen (MCSA) or the hapten 2,4-dinitrophenyl (DNP). Injection with either Ab1 activated a functional idiotypic (Id) network as evidenced by production of both anti-Id (Ab2) antibodies and anti-anti-Id (Ab3) antibodies. A subset of induced Ab3 (designated Ab3'), exhibited specificity for antigen (virus or DNP). In mice immunized with anti-Id antibodies (Ab2), production of Ab3 and Ab1' was also observed. In the MCSA system, antibody-induced Ab1' responses were effective in protecting mice from tumor development upon subsequent challenge with live virus. Furthermore, antigen-independent modulation of immunity to both viral and nonviral antigens was found to be thymus-dependent. Similar findings in other viral systems suggest that antibody-induced activation of Id networks may prove a viable alternative vaccine strategy that can elicit antigen-specific responses, and in some cases protection, in the apparent absence of exposure to antigen.

Introduction

One of the greatest challenges of modern immunology is the development of effective vaccines for such diverse diseases as cancer, hepatitis, and acquired immune deficiency syndrome (AIDS). Conventionally, viral and bacterial vaccines have consisted of attenuated (nonvirulent) strains of the pathogenic organism, or stocks which have been inactivated by heat, chemical treatment, or irradiation. However, each of these methods carries the

The study is dedicated to Dr. Eddie W. Lamon who died during preparation of this manuscript.
inherent risk that the vaccine may itself induce the disease, due to incomplete inactivation or the appearance of a virulent revertant in an attenuated strain. Modern molecular biology has offered alternative methods of producing safe and effective microbial vaccines, including expression of recombinant antigenic epitopes in nonpathogenic carriers such as vaccinia virus [1]. While this approach is valid for strongly immunogenic viral or bacterial epitopes, it is less promising in tumor systems involving less well-defined and more weakly immunogenic tumor antigens. Thus, the development of effective tumor vaccines still poses a significant challenge to modern immunologists.

One novel and exciting approach to tumor vaccine development involves the network hypothesis originally proposed by Jerne [2]. In this view of the immune system, antibodies interact not only with nominal antigen, but also with other antibody molecules during the course of an immune response. The antibody variable region contains two important sites necessary for these interactions to occur. They include the paratope (antigen combining site) and the idiotope, an immunogenic site which can be bound by the paratopes of other antibody molecules. A collection of unique idiotopes borne by any individual antibody is collectively referred to as the idiotype (Id) of that molecule. The immune system can thus be viewed as a network of interacting elements, which express unique Ids capable of eliciting specific anti-Id responses.

For example, an antigen may activate a population of B cells expressing antibody (Id, or Ab1) which bear distinct Id determinants and are capable of binding Ag through their paratopes (fig. 1). The Id determinants on Ab1 are also immunogenic and can stimulate a second population of lymphocytes expressing Ab molecules, termed anti-Id antibody (Ab2). Likewise, Ab2 can stimulate a third population of lymphocytes expressing anti-anti-Id antibodies (Ab3) which recognize and bind Ab2. A subset of the Ab3 response (Ab1') can also bind the original antigen. Thus, at least a portion of the Ab2 response possesses the capacity to stimulate an antigen-specific immune response. This Id cascade may play positive or negative regulatory roles in the response to nominal antigen.

Of particular interest for this discussion, Id or anti-Id reagents themselves may be used to induce specific immune responses in the absence of nominal antigen. This feature of the Id network lends itself to the development of effective vaccines, which would eliminate the need to purify large quantities of poorly defined or poorly immunogenic tumor antigens. The advent of hybridoma technology, and the resulting ability to produce large quantities of pure monoclonal antibody of desired specificity, has provided a quantum leap in the technology of Id vaccine development.

The immune network hypothesis as originally proposed by Jerne [2] was limited to B lymphocytes and their secreted antibodies. However, many reports have implicated antigen-specific and Id-specific regulatory T lymphocytes in Id-based regulation of immune responses [3–9]. These findings suggest that Id-specific T cells can interact with B cells to regulate Id*, antigen-specific immune responses and that Id-directed B-T lymphocyte cooperation is conceivably a general physiologic phenomenon. The recognition of Id determinants by T cells confers an added level of complexity to network regulation since B-T lymphocyte interactions may have either an inhibitory or stimulatory effect on a particular antigen-specific B cell, depending on the spectrum of lymphokines produced by the T cell. The added dimension of T cell involvement in Id-based regulation does not contradict the basic tenets of the immune network theory but instead may supplement it in a more global manner.
Many reports have described Id-based immune regulation in a number of different viral systems (summarized in table 1). Both polyclonal and monoclonal reagents have proven to be useful. However, the exquisite specificity and large scale production potential of monoclonal antibodies makes this the method of choice for vaccine development. A com-

**Table 1. Idiotype-based immune regulation in different viral systems**

| Family        | Virus                  | Injected Ab | Ab3(Ab1') | Protection | Comments | Ref. No. |
|---------------|------------------------|-------------|-----------|------------|----------|----------|
| Retroviridae  | M-MuSV/M-MuLV          | Ab1 (+)     | +         | + monoclonal |          | 13, 14   |
|               |                        | Ab2 (+)     | +         | monoclonal  |          | 15       |
|               | FeLV                   | Ab2 (+)     | +         | NR monoclonal |        | 12, 51   |
|               | MMTV                   | Ab2 (+)     | +         | monoclonal  |          | 52, 53   |
|               | HIV                    | Ab2 (+)     | +         | NR monoclonal |        | 62–66    |
| Papoviridae   | SV40                   | Ab2 (+)     | +         | polyclonal  |          | 49       |
|               |                        | Ab2 (+)     | +         | NR monoclonal |        | 50       |
|               |                        | Ab2 (+)     | +         | monoclonal  |          | 88       |
|               |                        | Ab2 (+)     | +         | polyclonal  |          | 89       |
| Hepadnavirida | Hepatitis B virus      | Ab2 (+)     | +         | polyclonal  |          | 54–57    |
| Reoviridae    | Reovirus type 3         | Ab2 (+)     | +         | monoclonal  |          | 10, 58   |
|               | Bluetongue virus        | Ab2 NR      | NR        | monoclonal  |          | 67       |
| Rhabdovirida  | Rabies virus           | Ab2 (+)     | 0         | polyclonal  |          | 11, 68   |
|               |                        | Ab2 (+)     | NR        | monoclonal  |          | 69       |
| Picornavirida | Polio virus type II     | Ab2 (+)     | 0         | monoclonal  |          | 61       |
|               | FMDV type A12           | Ab2 (+)     | +         | polyclonal  |          | 70, 71   |
|               | FMDV type O1           | Ab1 NR(+)+  | NR        | monoclonal  |          | 72       |
|               | Coxsackie virus B3      | Ab2 (+)     | +         | monoclonal  |          | 73, 74   |
|               | Coxsackie virus B4      | Ab2 NR(+)+  | NR        | polyclonal  |          | 75       |
|               | Enterovirus 70          | Ab2 NR(+)+  | NR        | monoclonal  |          | 96       |
| Orthomyxovirida | Influenza A virus     | Ab2 (+)     | +         | polyclonal  |          | 76       |
| Paramyxovirida | Sendai virus            | Ab2 (+)     | +         | monoclonal  |          | 47, 77, 78 |
|               | Newcastle disease virus | Ab2 (+)     | +         | polyclonal  |          | 79       |
|               | Respiratory syncytial virus | Ab2 (+)     | +         | polyclonal  |          | 80       |
| Herpesvirida  | Cytomegalovirus         | Ab2 (+)     | NR        | monoclonal  |          | 81       |
|               |                        | Ab2 (+)     | NR        | polyclonal  |          | 90       |
|               | Pseudorabies virus      | Ab2 (+)     | +         | polyclonal  |          | 82, 91   |
|               | Herpes simplex type II  | Ab2 NR(-)+  | -         | polyclonal  |          | 83       |
|               | Herpes simplex type I   | Ab2 NR(-)+  | NR        | polyclonal  |          | 84       |
| Togaviridae   | Rubella virus           | Ab2 (+)     | NR        | monoclonal  |          | 85       |
|               | VEE                     | Ab2 NR(+)+  | NR        | polyclonal  |          | 86       |
|               | Semliki forest virus    | Ab2 (+)     | +         | monoclonal  |          | 92       |
| Flaviridae    | JEV                     | Ab2 (+)     | NR        | polyclonal  |          | 87       |
| Coronavirida  | TGEV                    | Ab2 (+)     | NR        | monoclonal  |          | 93       |
|               | Mouse hepatitis virus   | Ab2 (+)     | +         | polyclonal  |          | 94       |

Id network activation by antibody alone against virus-induced tumor-associated antigens and viruses associated with infectious disease. HIV = Human immunodeficiency virus; FMDV = foot and mouth disease virus; VEE = Venezuelan equine encephalomyelitis virus; JEV = Japanese encephalitis virus; TGEV = transmissible gastroenteritis coronavirus.

a Activation of Id network by Id (Ab1) or anti-Id (Ab2) antibody.

b + = Response detected; - = response not detected; NR = not reported.

c + = Protection; 0 = no protection; - = increased pathogenicity; NR = not reported.

d Clonality of injected antibody (Ab1 or Ab2 – see column 2).
mon strategy [10–12] is to generate an anti-epitope monoclonal antibody (Ab1) that is associated with a protective response in the host (e.g., virus-neutralizing). The Ab1 is then used as an immunogen to elicit an anti-Id antibody (Ab2). Ideally, the Id borne by Ab1 should be located in, or sufficiently near, the antigen combining site of the antibody (paratope-associated), be interspecies cross-reactive, and be able to induce a second population of anti-Id antibody (Ab2). An Ab2 generated in this manner may present a complementary three-dimensional conformation sufficiently similar to the original viral epitope defined by Ab1. Exposure to the anti-Id alone could conceivably mimic the effects of exposure to viral epitopes or virus-induced antigens with none of the potential negative consequences. This idea is appealing with regard to the development of alternative vaccine strategies since anti-Ids could potentially supersede antigen in induction of Id+, antigen-specific responses. This approach is obviously attractive when considering vaccines against HIV, hepatitis, or other pathogens where employment of conventional vaccines (containing killed or attenuated virus) may be risky.

Our laboratory has been investigating antigen-independent modulation of immunity by monoclonal antibodies to both viral and non-viral antigens. In one system [13–15], we examined antibody-induced immune responses to a Moloney murine leukemia virus-induced cell surface antigen (MCSA). We also investigated antigen-independent immune responses to the well-defined M460 Id [16, 17], which is associated with the BALB/c immune response to the hapten 2,4-dinitrophenyl (DNP). This review describes the Id and antigen-binding specificities in the sera of mice injected with unmodified, homologous monoclonal antibody, in the absence of carrier molecules, adjuvants and antigen. Although the nature of the antigens themselves are different (viral vs. hapten), common features are observed in the immune responses generated after introduction of monoclonal antibodies within each Id system. In all experiments, passive immunization with Ab1 activated an Id network (fig. 1) which elicited both Ab2 and Ab3 responses, a portion of the latter exhibiting specificity for antigen (Ab1'). In mice passively immunized with anti-Id antibody (Ab2), production of Ab3 and Ab1' was also observed. In some experiments in the MCSA system, the resulting Ab1' responses proved to be effective in protecting the animals from tumor development upon subsequent challenge with live virus. In addition, we show that antigen-independent modulation of immunity to both DNP and Moloney murine sarcoma/leukemia virus complex (M-MuSV/ M-MuLV) is thymus-dependent.

Fig. 1. Schematic representation of the Id network. Antigen (Ag) induces and is recognized by lymphocytes expressing antibody bearing an Id (Ab1). Ab1 induces and is recognized by lymphocytes expressing anti-Id antibody (Ab2) and so on. A subset of Ab3 (designated Ab1') not only recognizes Ab2, but also reacts with the original Ag in the circuit and may share idiotopes with Ab1. Other subsets of Ab3 (designated Ab1', Ab1" etc.) represent parallel sets which may share idiotopes with Ab1 and Ab1', but have distinct binding specificities. Likewise, a subset of Ab4 (designated Ab2'), which recognizes Ab3, can also bind Ab1 and may share idiotopes with Ab2. Other Ab4 subsets represent parallel sets with the same characteristics described above.
The Viral Story: M-MuSV/M-MuLV

The M-MuSV/M-MuLV is composed of M-MuSV, a replication-defective retrovirus that transforms cells and induces tumor formation, and M-MuLV, a helper virus necessary for M-MuSV replication [18, 19]. Injection of M-MuSV/M-MuLV into mice induces localized sarcomas which spontaneously regress in immunocompetent hosts [20]. This regression event is dependent upon specific humoral and cell-mediated immune responses [21-26] which are directed at antigens encoded by the helper virus [27-29].

Our laboratory has isolated and characterized three hybridoma clones secreting monoclonal IgM,k antibodies, which bind M-MuSV/M-MuLV-infected cells [13, 14]. The monoclonal antibodies (mAb) bind a cytoplasmic and cell surface Friend-Moloney-Rauscher group-specific antigen as determined by ELISA and immunofluorescence. Immunoelectron microscopy revealed antibody binding to virus-infected cell surfaces, but not to budding or mature virus particles [13]. In agreement with the immunoelectron microscopy, the mAbs were unable to neutralize virus, but were active in complement-mediated and cell-mediated cytotoxicity of infected cells, suggesting that these antibodies were specific for the gp85gag cell surface antigen. To test this hypothesis, we obtained a mutant clone of M-MuLV [30] which produces infectious virus, but lacks the genes for the transmembrane leader sequence and thus does not produce glycosylated cell surface gp85gag. When NIH3T3 cells were transfected with proviral DNA from both mutant and wild-type M-MuLV, both cells expressed cytoplasmic antigen detectable by immunofluorescence with one of our IgM mAb. However, only cells transfected with the wild-type proviral DNA (containing cell surface gp85gag) were susceptible to complement-mediated lysis induced by this antibody. These data provide direct evidence that the cell surface target of these antibodies is an epitope contained within gp85gag. The in vitro characterization of these mAbs is summarized in table 2 [14].

Due to the in vitro reactivity of the mAbs with an MCSA, we attempted to determine whether they could exhibit antitumor activity in vivo [13]. BALB/c mice received an intramuscular inoculation with an oncogenic dose of M-MuSV/M-MuLV. Twice a week thereafter, the mice were inoculated intraperitoneally with either MCSA-specific mAb, an isotype-matched control mAb, or saline. Tumor size was measured at the site of virus injection every 3-4 days. In a representative experiment shown in figure 2, two of the MCSA-specific mAbs (KL-5 and KL-9) demonstrated pronounced in vivo antitumor activity, providing complete or nearly complete protection from tumor development. This effect was not due to nonspecific activity of the IgM mAbs, since mice treated with the control mAb, MOPC104E, were not protected from tumor development. The in vivo protective effect of MCSA-specific IgM was partially dependent on the presence of functional T cells. When athymic (nu/nu) and euthymic (nu/+)) mice were inoculated with virus, then treated with mAb, sarcoma development and growth could be inhibited, and survival time increased, in nu/nu mice receiving M-MuSV-specific IgM [data not shown]. However, all nu/nu mice eventually died from the overwhelming tumor burden while their euthymic littermates receiving identical treatment recovered completely [13].

These in vivo experiments demonstrated that each of the MCSA-specific IgM mAbs could exhibit antitumor activity in vivo, but these results did not reveal the mechanism of protection. There are several possible mechanisms. The most direct mechanism of protec-
Fig. 2. Primary Moloney sarcoma growth inhibition by IgM monoclonal antibodies KL-5 and KL-9. Each point represents the geometric mean increase in thigh diameter from 4 BALB/c female mice inoculated with M-MuSV. O = Animals treated with PBS; △ = animals treated with MOPC104E, 150 μg/injection i.p.; □ = animals treated with KL-5 IgM, 150 μg/injection; • = animals treated with KL-9 IgM, 150 μg/injection. Arrows indicate days of treatment, including day 1 after virus infection not shown. Actual thigh diameters (log10 mean ± SEM, mm) at peak tumor size (day 12) were PBS-treated 0.91 ± 0.064, MOPC104E-treated 0.94 ± 0.076; KL-5-treated 0.74 ± 0.054, KL-9-treated 0.67 ± 0.005 [modified from 13].

Table 2. mAb used in this study

| Designation | H and L | Specificity | RS1.1.3 reactivity |
|-------------|---------|-------------|-------------------|
| KL9         | IgM, κ  | MCSA        | +                 |
| KL5         | IgM, κ  | MCSA        | +                 |
| 3.2.3       | IgM, κ  | MCSA        | +                 |
| 7.1.2.4     | IgM, κ  | MCSA        | +                 |
| DNP 57-1    | IgM, κ  | DNP         | ±                 |
| HPCM2       | IgM, κ  | PC          | –                 |
| BH8         | IgM, κ  | PC          | –                 |
| M25         | IgM, κ  | PC          | –                 |

H and L represent H and L chain composition of each mAb determined by ELISA. Each mAb was assayed for reactivity with RS1.1.3 in an ELISA. + = Positive (OD400 ≥ 0.50); – = negative (OD400 < 0.10); ± = weakly reactive, in one experiment DNP 57-1 reacted weakly with RS1.1.3 (OD = 0.11). However, the titer at equal IgM concentrations was 7-fold lower than KL9. In subsequent experiments DNP 57-1 was negative [modified from 14]. PC = Phosphorylcholine.
Table 3. Cell-mediated cytotoxicity versus Ha2 target cells, by spleen cells from M-MuSV-inoculated mice treated with monoclonal IgM antibodies

| Effector cells/wella | Treatment groupsb |
|----------------------|-------------------|
|                      | KL-5             | KL-9             |
| Δ% reductionc        | p <d             | Δ% reductionc    |
|                      |                   | p <d             |
| 10,000               | 49               | 0.025            | 68               | 0.005            |
| 5,000                | 56               | 0.005            | 33               | 0.20             |
| 2,500                | 53               | 0.001            | 33               | 0.10             |
| 1,250                | 26               | 0.30             | 34               | 0.10             |
| 625                  | 54               | 0.01             | 55               | 0.02             |
| 312                  | 46               | 0.02             | 47               | 0.05             |
| 156                  | 26               | 0.30             | 37               | 0.10             |

a Spleen cells/10μl well; 10,000 corresponds to E:T of 50:1. All effector cells in this experiment were treated with trypsin prior to assay.
b Four BALB/c mice/group inoculated with M-MuSV 30 days previously and injected intraperitoneally twice weekly with 150 μg IgM KL-5 or KL-9 in ascitic fluid. Last treatment on day 22 after virus injection. Fractionation experiments have previously shown that specific cytotoxicity from spleen cells of BALB/c mice 30 days or longer after virus injection is mediated by non-T cells [23].
c % reduction compared to PBS-treated group. It is extrapolated from % remaining target cells. For data to be combined from different Microtiter plates, the number of remaining target cells in each well was normalized to the control wells containing target cells and medium only. n = 24, for each effector cell concentration. log10 mean ± SEM normalized target cells remaining at the 10,000 effector concentration were: PBS-treated 1.89 ± 0.095, KL-5-treated 1.6 ± 0.070, and KL-9-treated 1.4 ± 0.10.
d Estimated by Student’s t test, compared to PBS-treated group at each effector cell concentration [modified from 13].

that antigen-specific activation of the immune system resulted from passive immunotherapy with MCSA-specific IgM mAbs.

Since functional T cells were required to achieve complete tumor resistance during mAb therapy [13], we proposed that the MCSA-specific monoclonal antibodies induced antigen-specific cell-mediated immune responses in vivo. To test this hypothesis, mice were inoculated with virus, with or without subsequent mAb administration, as described above. Thirty days after virus injection, spleen cells from virus-inoculated mice were assayed for cytotoxic activity against M-MuSV-transformed target cells. As expected, spleen cells from virus-inoculated mice were lytic for tumor cells in vitro. Surprisingly, spleen cells from virus-inoculated mice subsequently given mAb injections exhibited more cytotoxic activity as compared to mice inoculated with virus only (table 3). The cytotoxic activity of the effector cells was not due to passively adsorbed monoclonal antibody, since exposure of the splenocytes to trypsin did not reduce their ability to kill transformed targets [13]. These data suggest that administration of MCSA-specific monoclonal IgM activated a specific immune response, resulting in the generation of tumor-specific cytotoxic effector cells in vivo.

In addition to cytotoxic effector cells, both B cells and helper T cells are important in the normal immune response to M-MuSV/M-MuLV. Thus, we hypothesized that B cells (and, by extension, helper T cells) were activated by exposure to the MCSA-specific IgM mAb, representing Ab1. To test this hypothesis, we examined the MCSA-specific antibody response in the sera of mice treated with Ab1. Mice were inoculated with virus, with or without subsequent IgM Ab1 administration as described above, and observed for tumor development. At various time points during the course of tumor development and regression, sera were collected and examined for titers of MCSA-specific antibodies in an ELISA [14]. By employing isotype-specific secondary reagents, we were able to distinguish the passively administered IgM antibodies from antigen-specific antibodies produced in vivo. The
Fig. 3. Effect of passive IgM injection on M-MuLV-specific serum antibody titers. Sera were collected from mice on the indicated days after virus inoculation on day 0, and assayed for M-MuLV-specific antibodies by ELISA. Day 0 values are the log10 mean ± SEM of 12 normal mouse sera titers. ● = Mice inoculated with virus on day 0 followed by no further treatment; ○ = mice inoculated with virus on day 0 followed by KL-9 IgM injections (100 μg/mouse) on days indicated by arrows; □ = mice which were not inoculated with virus, but were injected with KL-9 IgM on days indicated by arrows. a M-MuLV-specific IgG1 titers. b M-MuLV-specific IgG2a titers [modified from 14].

results of this serological assay paralleled those of the cellular assay described above, i.e., higher titers of MCSA-specific non-IgM antibodies were found in the sera of mice which had received IgM mAb injections following virus inoculation, compared to those animals which were inoculated with virus only (fig. 3). The MCSA-specific serum antibodies induced by IgM Ab1 administration were predominantly of the IgG1 and IgG2a isotypes, with minor contributions from the IgG2b and IgG3 isotypes. The presence of MCSA-specific IgG1 is particularly intriguing, since this isotype is almost completely absent from the normal antibody response to virus challenge in BALB/c mice [14]. These results suggest that administration of IgM Ab1 activated antigen-specific B cells in vivo,
Fig. 4. Anti-idiotypic serum titers after passive IgM injection. The same sera assayed in figure 3 were also assayed for anti-idiotypic antibodies by using ELISA plates coated with KL-9 IgM or with HPCM2 IgM. The results shown were calculated by subtracting the HPCM2-binding titers from the KL-9-binding titers of the same sera. The highest HPCM2-binding titers at the peak of the response were 40, i.e., >200-fold lower than anti-KL-9 titers. The symbols are described in the legend to figure 3 [modified from 14].

which secreted antigen-specific antibodies of isotypes distinct from that of the original Ab1.

One of the most interesting and exciting findings of these studies occurred serendipitously. In the initial serological studies, mice were examined following inoculation with virus, with or without subsequent Ab1 treatment. However, no mice received Ab1 treatment in the absence of virus inoculation. Therefore, the experiment was expanded to include a group of mice treated in this fashion. Thus, four groups of mice were examined for the presence of MCSA-specific serum antibody titers: (1) normal, (2) inoculated with virus only, (3) inoculated with virus followed by IgM Ab1 treatment, (4) treated with IgM Ab1 in the absence of virus inoculation. As expected, group I had undetectable titers of MCSA-specific antibodies, group II had measurable titers of predominantly IgM antibodies, and group III had elevated titers of MCSA-specific IgG1 and IgG2a antibodies. Surprisingly, the MCSA-specific titers in the sera of group IV mice were essentially identical to those found in group III, suggesting that the IgG1 and IgG2a titers seen in group III resulted primarily from exposure to the IgM Ab1, independent of exposure to the virus (fig. 3). Thus, the injection of IgM Ab1 had a vaccine effect, in that it resulted in the activation of antigen-specific B cells in vivo.

It is difficult to envision how injection of antigen-specific antibody (Ab1) can result in activation of B cells specific for the same antigen, unless one invokes the Id network as discussed above. If we hypothesize that Ab1 injection initiates the Id cascade, then we should be able to detect several antibody specificities in the sera of treated mice: Ab2, or anti-Id antibody which binds specifically to the Id determinants on the injected Ab1; Ab3, or anti-anti-Id antibody which binds specifically to the Id determinants on the Ab2; and Ab1', a subset of Ab3, which binds not only to Ab2 but also to the nominal antigen, in this case MCSA. Ab1' would be represented by the increased titers of MCSA-specific IgG1 and IgG2a which were found in the sera of Ab1-injected mice.

Therefore, these same sera were examined for Ab2 titers, in an ELISA using plates coated with the immunizing Ab1 or an isotype-matched control mAb [14]. Since the coated
mAbs were IgM, we used IgG subclass-specific secondary reagents to detect Ab2 titers. High titers of Ab2 were found in group III (virus plus Ab1) and group IV (Ab1 only), but not in detectable quantities in groups I or II (fig. 4, 5). Thus, the first step in the Ab1-induced Id cascade, the production of Ab2, was confirmed.

To detect Ab3, we employed an ELISA in which plates were coated with RS1.1.3, a monoclonal IgG1 Ab2 which recognizes a common idiotope present on our panel of MCSA-specific IgM mAbs [15]. The hybridoma secreting RS1.1.3 was produced by immortalizing B cells from a mouse immunized with the IgM mAb, 7.1.2.4, and screening for binding to several different IgM mAbs. RS1.1.3 was identified by its ability to bind specifically to the MCSA-specific IgM mAbs, but not to unrelated IgM mAbs of disparate specificities. When sera from the four groups of mice described above were assayed for anti-RS1.1.3 titers, only group III (virus plus Ab1) and group IV (Ab1 only) sera displayed significant titers (table 4). These Ab3 titers consisted of the IgG2a, IgG2b, and IgG3 isotypes [14]. Thus, the second step in the Ab1-induced Id cascade, the production of Ab3, was confirmed.

In this series of studies, Ab2 (fig. 4, 5a), Ab3 (table 4), and Ab1' (fig. 5b) were detectable in the sera of mice immunized with IgM Ab1. We believe these data constitute the first description of a complete Id network induced by exposure to antigen-specific mAb, in the absence of apparent exposure to the nominal antigen itself. In addition to the serological observations, we also observed primed cellular responses (table 3), which would suggest that Id manipulation of the immune response may serve as a potent route of vaccination. However, while Ab1 did provide protection in a therapeutic manner (fig. 2), it failed to generate protection in a prophylactic manner [data not shown], even though prior immunization with Ab1 induced both humoral and cellular responses.

Following the demonstration that the Id cascade was activated by Ab1, we examined the effect of Ab2 administration on the subsequent immune response [15]. Mice were immunized intraperitoneally with varying doses of RS1.1.3 suspended in saline without adjuvant, and their sera were then analyzed for
Table 4. Ab3 titers of KL9 IgM-injected mice

| Days | NMS       | MuSV      | MuSV + KL9 | KL9 only | Isotype |
|------|-----------|-----------|------------|----------|---------|
| 15   | 0.52 (0.05) | 0.85 (0.11) | 2.51 (0.01) | 2.60 (0.14) | Total   |
| 20   | 0.65 (0.13) | 2.62 (0.20) | 2.69 (0.18) |          |         |
| 25   | 0.94 (0.24) | 2.36 (0.20) | 2.45 (0.03) |          |         |
| 15   | 1.41 (0.04) | 1.45 (0.15) |          |          | IgG2a   |
| 20   | 1.73 (0.14) | 2.09 (0.09) |          |          |         |
| 25   | 0.92 (0.04) | 1.30 (0.38) |          |          |         |
| 15   | 0.88 (0.35) | 1.48 (0.06) |          |          | IgG2b   |
| 20   | 1.28 (0.11) | 0.99 (0.23) |          |          |         |
| 25   | 1.03 (0.07) | 0.73 (0.26) |          |          |         |
| 15   | 0.74 (0.08) | 1.01 (0.06) |          |          | IgG3    |
| 20   | 1.12 (0.06) | 1.28 (0.06) |          |          |         |
| 25   | 0.76 (0.12) | 0.93 (0.03) |          |          |         |

The sera assayed in figures 4 and 5 were assayed for Ab3 antibodies by using ELISA plates coated with purified RS1.1.3 (monoclonal Ab2). Results are presented as log10 mean ± SEM of triplicate sera each time point. Day = Days after virus inoculation; NMS = normal mouse sera; MuSV = sera from mice inoculated with virus on day 0; MuSV + KL9 = sera from mice inoculated with virus on day 0, followed by KL9 IgM on days 1, 4, 6, 8, 11, and 13 (100 µg/mouse/injection); KL9 only = sera from mice injected only with KL9 IgM (no virus inoculation); isotype = isotype probed in the ELISA (total = all isotypes except IgG1) [modified from 14].

Ab3 (binding to RS1.1.3) and Ab1’ (binding to MCSA). Mice immunized with increasing quantities of Ab2 had elevated titers of serum Ab3, which was undetectable in sera from nonimmune mice. IgM and IgG2a were the dominant isotypes, with IgG2b and IgG3 also detectable (fig. 6a). When the same sera were screened for Ab1’ antibodies, only the IgM and IgG1 isotypes were detected (fig. 6b). These data show that immunization with Ab2 activated the Id network, resulting in the production of Ab3 and Ab1’, similar to the results described earlier with Ab1 immunization.

While the serological results following Ab1 or Ab2 immunization were similar, a marked difference was seen in the induction of protective immunity. As described above, Ab1-immunized mice displayed high titers of antigen-specific antibodies, as well as increased cytotoxic cellular activity, but were no more resistant to tumor development than naive control mice. When mice were immunized with Ab2 prior to virus challenge, however, effective immunity was achieved [15]. The Ab2-immunized mice experienced a 65–70% reduction in tumor size during peak tumor development (7–9 days after virus challenge), with an overall reduction in tumor load for the entire course of the experiment of 75% when compared to nonimmune euthymic controls (fig. 7). This protective effect appeared to be T cell-dependent, since athymic (nu/nu) mice immunized with Ab2 were not protected against sarcoma growth. (The apparent decrease in tumor size of the athymic mice after day 8 is due to death of mice with...
Fig. 6. Ab3 and Ab1' serum antibody responses to immunization with RSI.1.3. Mice were immunized with the indicated μg doses of purified RSI.1.3 every 3–4 days, then rested 5 days before collection of sera. A dose of 0 represents normal mouse sera. The sera were assayed for Ab3 antibodies using ELISA plates coated with RSI.1.3 (a) and for Ab1' antibodies using ELISA plates coated with YAC extract (b). The data are presented as the log_{10} ± SEM of the endpoint titers of five mice per group. An endpoint titer of 0 represents values below the limits of detection in this assay. IgG1: IgG2a; IgG2b; IgG3; IgM. * p < 0.10; ** p < 0.01; * p < 0.005; ** p < 0.0005 (Student's t test), compared to 0 dose [modified from 15].

Fig. 7. Effect of Ab2 immunization on subsequent tumor development. Euthymic (○, □) and athymic (■, □) mice were either immunized with five injections of 50 μg RSI.1.3 (○, ■) or not immunized (□, □). The mice were rested 7 days following the last injection, then challenged with M-MuSV/M-MuLV intramuscularly in the right thigh. Thigh diameters were measured for 28 days. The results are presented as the geometric mean increase in thigh diameter for each group. The log_{10} mean ± SEM (and geometric mean) of percent of control tumor burden for the euthymic mice were 2.00 ± 0.09 (100) for the normal mice, and 1.40 ± 0.06 (25) for the RSI.1.3-immunized mice; this represents a significant reduction (p < 0.005, Student's t test). The apparent decrease in mean tumor size after day 9 in the athymic mice is due to the death of the mice with the largest tumors at that time, and not to true reduction in tumor size. It should be noted that all athymic mice died from tumor growth by day 15, whereas all euthymic mice showed complete regression of tumors by day 27 [modified from 15].
the largest tumors and not due to tumor regression). All athymic mice died by day 15 after virus challenge while their nu/+ littermates completely recovered from tumor development. These results indicate that T cell involvement is necessary for resistance to tumor development in Ab2-immunized mice.

In a separate experiment, Ab2 mAb (RS1.1.3) was administered to mice after inoculation with an oncogenic dose of virus (i.e., during tumor development), resulting in a 50% increase in tumor size compared to untreated control mice [15]. The mechanism for this increased susceptibility to tumor development is unclear, but may be due to a competitive interaction between the Ab2 and the virus-induced tumor antigens. Perhaps the Ab2 interacts with Id+ B cells and/or T cells, preventing these responses from acting against the antigens displayed on the tumor cells. Therefore, Ab2 administration is effective prophylactically but not therapeutically, the converse of which is true for Ab1 administration (see above).

Finally, we wished to determine if alteration of the adult Id repertoire would have an effect on tumor susceptibility. Based on work by Vakil et al. [31], we injected Ab1 or Ab2 into neonatal BALB/c mice, in an attempt to clonally delete the lymphocytes which are bound by these Id reagents. The mice were then rested until adulthood (6–8 weeks) and challenged with an oncogenic dose of virus. The results were quite surprising. Mice which had been neonatally injected with Ab2, in an attempt to eliminate anti-Id lymphocytes, developed much larger tumors than control littermates (553% of control tumor burden; p < 0.0005). These data suggest that elimination of anti-Id lymphocytes rendered the mice less able to effectively respond to virus challenge. This is surprising, since anti-Id lymphocytes would be expected to exert a feedback regulatory effect on the antitumor response, and thus their elimination would allow the antitumor response to proceed more vigorously. It seems, therefore, that the anti-Id lymphocytes play important positive, rather than negative, regulatory roles in the antitumor response. At the very least, these data emphasize the importance of a balanced Id cascade in response to virus challenge.

The Hapten Story: Dinitrophenyl

Although M-MuSV/M-MuLV-specific antibody responses can be induced by injection of Ab1 or Ab2, neither the antigens, nor the Id(s) of antibodies responding to these antigens have been well characterized. In order to more fully examine antigen-specific B cell activation by unmodified Ab, we decided to investigate the possibility that our findings in the M-MuSV/M-MuLV system could also be extended to a more well-defined Id system. We examined the responses to both a hapten-specific monoclonal IgM bearing the M460 Id (Id+ antibody or Ab1), and to an anti-M460 Id mAb (representing anti-Id or Ab2) [16, 17]. The M460 Id has been previously characterized in terms of its expression [9, 32, 33], germline V_{H} gene family [34], and associated reactivity [35].

Mice were passively immunized with unmodified Id460+, DNP-specific IgM (Ab1), in the absence of exogenous adjuvant or antigen, and sera were examined for induced Ab2. To
Table 5. Antibody designations and specificities

| Designation | H + L chain | Specificity   | Major Id family* | FDS-1 reactivity |
|-------------|-------------|---------------|-------------------|------------------|
| M460        | α, κ        | DNP           | 36–60             | +                |
| M315        | α, λ₂       | DNP           | 36–60             | –                |
| EPC109      | α, κ        | Levan         | 36–60             | –                |
| J558        | α, λ₁       | DEX           | 36–60             | –                |
| M104e       | µ, λ₁       | DEX           | 36–60             | –                |
| N20         | µ, κ        | Anti-IdX (J558, M104e) | 36–60          | –                |
| MM60        | µ, λ₃       | Anti-anti-T15 | 7183              | +                |
| 1-21        | µ, λ₁       | DEX           | 7558              | –                |
| BH8         | µ, κ        | PC            | S107              | –                |
| PB2-2       | µ, κ        | P. pneumo.    | 36–60             | +                |
| 57.1        | µ, κ        | DNP           | 36–60             | +                |

Panel of mAb against which serum from BALB/c mice immunized twice with 100 µg/mouse 57.1 was screened. All antibodies listed were immobilized on ELISA plates [16]. Levan = Bacterial levan; anti-IdX = anti-Id specific for more than one Id; DEX = α1,3-dextran; PC = phosphorylcholine; P. pneumo. = Pasteurella pneumotropica [modified from 16].

* V₇ gene family.

detect Ab2, ELISA plates were coated with the immunizing Ab1 (this particular antibody was given the numerical designation 57.1), followed by immune sera or normal mouse sera (control), and subsequent incubation with IgG subclass-specific secondary reagents. Passive immunization with unmodified DNP-specific IgM (Ab1) was found to produce measurable Ab2 responses. When the Id specificity of the induced Ab2 was examined in more detail by evaluating immune and nonimmune serum binding to a panel of antibodies that represented other major Id families (V₇ gene families), the induced Ab2 was found to be restricted to individual Id present on the immunizing IgM (table 5, fig. 8). The Id-specific IgG1 antibody titer against DNP-specific IgM mAb was greater than 4,000; however when the same sera were tested against a panel of idiotypically distinct monoclonal antibodies, IgG1 titers were not significantly different from those found in normal serum [16]. The response was not anti-isotypic since immune sera did not bind any of the other IgM mAb in the panel. The exquisite specificity of the serum Ab2 response in DNP-specific IgM injected mice indicates that the response is directed against individually idiotopes on the injected antibody. It is not clear at the present time if these idiotopes contribute to the M460 Id since serum Ab2 did not recognize other Id460⁺ antibodies in the panel. When the serum Ab2 response was probed further, it was found to be partially dose-dependent to increasing quantities of injected DNP-specific IgM [data not shown].

The induction of Ab2 also required the presence of functional T cells. Athymic (nude) and euthymic mice were injected with identical quantities of DNP-specific IgM, and total serum IgG anti-Id titers examined in an ELISA. The immune sera from euthymic
mice generated titers of serum anti-Id which were approximately 1,000-fold higher than immune sera from athymic mice receiving the same quantity of DNP-specific IgM (fig. 9). Serum titers of anti-Id from the athymic animals were not significantly different from nonimmune controls.

To detect Ab3, we employed an ELISA assay in which plates were coated with FD5-1, a monoclonal IgG1 Ab2 which recognizes the M460 Id. The same sera from DNP-specific IgM-injected mice analyzed for the presence of Ab2 were examined in parallel for FD5-1-binding antibody (Ab3). Mice undergoing an Ab2 response could also be shown to produce Ab3. The Ab3 generated in response to DNP-specific IgM injection bound specifically to Ab2; no binding to an idiotypically unrelated IgG1, k mAb could be demonstrated (fig. 10a, b). In addition, a subset of Ab3 with specificity for antigen (Ab1') was also detected by

---

Fig. 8. Titration curves of sera from BALB/c mice illustrating the anti-Id response after secondary injection with 100 μg/mouse of 57.1. Specificity of serum anti-Id binding was assayed by coating individual ELISA plates with one of the mAb listed in table 5 followed by serial 2-fold dilutions of sera and subsequent enzyme-conjugated anti-IgG1 antisera. Sera from 5 mice injected with 57.1 were pooled. The data are represented as the absorbance at OD450 vs. the serum dilutions. Serum IgG1 antibody titers were measured by ELISA and calculated by regression analysis.

--- = Immune sera binding 57.1; --- = immune sera binding other antibodies in panel; --- = normal mouse sera binding to all antibodies in panel. The data are represented as the mean absorbance value ± SD [modified from 16].

Fig. 9. Thymus dependency of anti-Id response. Athymic (nu/nu) and euthymic (nu/+ ) mice were injected twice with 100 μg of 57.1. Serum anti-Id was assayed by antibody binding to 57.1. Titers of serum anti-Id from (nu/+ ) mice injected with 57.1 were significantly higher than from (nu/nu) mice immunized in parallel or unimmunized controls. The plates were probed for total serum IgG. The data are represented as the log10 mean ± SD of the endpoint titers of individual sera from each group [modified from 16]. NMS = Normal mouse sera; IMM = immune sera.
Fig. 10. Titration curves of pooled sera from BALB/c mice illustrating the idiotypic specificity of induced Ab3. Specificity of serum anti-Id binding was assayed by coating individual ELISA plates with either FD5-1 or PDG-1 followed by serial 2-fold dilutions of immune sera and subsequent enzyme-conjugated isotype-specific antisera. The data are represented as the absorbance at OD540 vs. the serum dilutions. a Serum Ab3 response probed for IgM. b Serum Ab3 response probed for IgG2a, IgG2b, and IgG3. —— = immune sera binding FD5-1; ——— = immune sera binding PDG-1. The data are represented as the mean of duplicate absorbance values ± SD. a SD values less than 0.023 are not represented [modified from 16].

Fig. 11. Antigen inhibition of Ab3 binding to FD5-1. a Serum Ab3 response probed for IgM. b Serum Ab3 response probed for IgG2a, IgG2b and IgG3. Conjugates include: Δ = NP-BSA; ● = OX-BSA; A = DNP-BSA; □ = α1,6 DEX-BSA; ○ = BSA alone, and ● = FD5-1. The data are represented as the mean absorbance value from two to four replicate wells [modified from 16].

probing for antibodies binding to DNP-KLH. To determine if Ab1' was contained within the Ab3 set of anti-Id binding antibody, several hapten-BSA conjugates (including (4-hydroxy-3-nitrophenyl) acetyl (NP), 4-ethoxy-methylene-2-phenoxazo-5-one (OX), and DNP) and dextran-BSA were tested for their ability to compete for the binding of serum Ab3 to Ab2 (FD5-1)-coated plates. In the M460 Id system, mice injected with DNP specific monoclonal antibody generate IgM (Ab1') antibodies that were inhibited from binding to Ab2-coated ELISA plates by DNP-BSA, and to a lesser extent by OX-BSA and NP-BSA (fig. 11a). The IgG component of the response was more restricted in that only DNP-BSA was able to inhibit the binding of serum Ab1' to Ab2-coated plates (fig. 11b).
Fig. 12. Titration curves for sera from BALB/c mice, illustrating the thymus dependence of the anti-anti-Id response. Athymic (nu/nu) and euthymic (nu/+) mice were injected 4 times with FD5-1 (for a total of 80 µg). Sera from 3–5 mice injected with FD5-1 were pooled. Specificity of serum IgM Ab3 binding was assayed by coating individual ELISA plates with either FD5-1 or AB1-2, followed by serial 2-fold dilutions of immune sera and subsequent enzyme-conjugated iso-type-specific antisera. a Serum binding to FD5-1-coated plates. b Serum binding to AB1-2-coated plates. The data are represented as the mean of duplicate absorbance values [modified from 17]. NMS = Normal mouse sera; IMM = immune sera.

Both experiments revealed that the addition of homologous antibody (FD5-1) produced the greatest degree of inhibition suggesting that a significant fraction of induced Ab3 have Ag specificities other than DNP (parallel sets). However, these findings indicate that a portion of the DNP response we designated as Ab1' is indeed a subset of Ab3 as defined by FD5-1 binding.

Whereas both Ab3 and Ab1' responses could be observed in euthymic mice, no measurable Ab3 responses were detected in nude mice receiving identical quantities of unmodified DNP-specific IgM [data not shown]. Thus, both steps in an Ab1-induced Id cascade, the production of Ab2 and Ab3 were confirmed in the M460 Id system. The data also demonstrate that antigen-independent induction of Ab2 and Ab3 are thymus-dependent.

In the previous study, it was shown that injection of DNP-specific IgM (Ab1), in the absence of adjuvants or Ag, induced Ab2 and Ab3 (including Ab1'). The results suggested but did not prove that the anti-Id antibodies induced were capable of mimicking Ag and could, therefore, elicit Ag-specific responses. To investigate further the Id interactions in this system, mice were injected with the anti-M460 Id mAb, FD5-1 (representing anti-Id or Ab2) [17]. An induced IgM Ab3 response was detected which was thymus-dependent and idiotypically specific for FD5-1 (fig. 12a, b). The serum Ab3 responses and Ab1' were detectable only in the IgM isotype; no specific IgG responses were observed. Additionally, injection of mice with FD5-1 induced T cell-dependent IgM responses against the haptens DNP, NP, and OX (fig. 13a–f). When the specificity of serum Ab1' binding from FD5-1-injected mice was evaluated by antigenic inhibition, binding of serum Ab1' to DNP-BSA was inhibitable by DNP-lysine, whereas equivalent concentrations of lysine alone had no inhibitory effect [17]. In agreement with our findings in the M-MuSVM-MuLV system, we have shown that activation of the Id network can be accomplished by injection of either Ab1 or Ab2. Sera from mice injected with anti-M460 Id mAb (FD5-1) contain anti-anti-Id antibodies, and the resulting network perturbation generates antigen-specific antibodies (Ab1') produced in the absence of Ag exposure.
Fig. 13. Titration curves for sera illustrating the thymus dependence of the Ab1+ response. Sera were probed for IgM. These are the same sera as used for the results illustrated in figure 12. The sera were assayed for Ab1+ by coating ELISA plates with DNP-BSA (a, b), NP-BSA (c, d), and OX-BSA (e, f). a, c, e Pooled sera from euthymic (nu/+ ) mice. b, d, f Pooled sera from athymic (nu/nu) mice. ▲, ● = Immune sera from FD5-1-injected mice; △, ○ = normal mouse sera. The data are represented as the mean of duplicate absorbance values ± SD [modified from 17].

Discussion

Antibody-induced modulation of immunity is a novel immunotherapeutic strategy that has the capacity to boost antigen-specific immune responses against virus-induced tumor-associated antigens or virally induced cell surface epitopes associated with infectious disease. Immunization with antibody alone can potentially supersede antigen in the induction
of Id$^*$, antigen-specific responses and circumvents the risks of exposure to infectious agents. The idea of utilizing anti-Id in place of conventional antigen as an alternative vaccine strategy had originally been proposed by Nisonoff and Lamoyi [36], who noted that antigen and an anti-Id may sometimes share related epitope(s). Subsequent reports also broadened the classification of anti-Id to include Ab2α, β, γ, etc. [37, 38] in order to describe in detail the juxtapositioning of Ab1, Ab2, and antigen with regard to idiotope and antigen binding specificities. A great deal of attention has been focused on Ab2β, the 'internal-image anti-Id', since these antibodies are proposed to mimic the immunological properties of antigen and have been considered to be the primary candidates for anti-Id vaccines. The 'internal-image' concept may be misleading however, since such terms imply stereochernical identity between anti-Id and nominal antigen. Furthermore, noninternal image Ab2 has been shown to induce antigen-specific responses [39–41] and thus, participate in functionally significant IId interactions. Recommended use of the term 'network antigens', suggested by Köhler et al. [42] may therefore be a more appropriate way to describe epitopes present on these anti-Id antibodies.

A variety of different anti-Id antibodies may thus potentially represent constructs of viral antigen that are nonvirulent, and nonproliferating, but nonetheless, antigenic in that they are capable of producing virus-specific immune responses in the absence of antigen. We have concentrated our efforts to further investigate these antibody-induced immune responses. Using an MCSA and the hapten, DNP, which are associated with distinct Ids, we observe common features in the immune responses generated after introduction of monoclonal antibodies within each Id system.

These findings demonstrate that immunization of BALB/c mice with monoclonal IgM specific for either MCSA or DNP (i.e., Ab1) activates a functional Id network, which resulted in production of both Ab2 and Ab3. The same sera were also found to contain antigen-specific antibodies (Ab1'). We have also demonstrated that immunization with Ab2 also activates the Id network. Thus, the proposed Id network may be activated by either Ab1 or Ab2, both of which lead to production of antigen-specific (Ab1') responses. In all experiments, injection of unmodified monoclonal Ab1 or Ab2 occurred in the absence of exogenous adjuvant or antigen (e.g., virus or DNP), indicating that native antibody alone is suitable as an effective immunogen. The thymus dependence of immune responses observed both in vitro and in vivo as reflected by immune network activation and by protection experiments, respectively, was apparent in both Id systems and indicate that T cells are an important component of antigen and Id-directed immune responses.

Id-directed T cell interactions that result in antigen-independent generation of Ab2, Ab3, and Ab1' can conceivably occur by one (or more) mechanisms. The current paradigm of T cell recognition involves antigen presentation to the T cell receptor by antigen-presenting cells. In the case of CD4+ T_H cells, this occurs in the context of major histocompatibility (MHC) class II antigens. Thus, external antigen is presented as a processed peptide in the antigen-presenting groove of a cell surface MHC class II molecule. This configuration allows the joint recognition of antigen and self MHC by the T cell receptor and triggers these T_H cells to function as helper cells. Whether such antigen processing and presentation is required for T-dependent Id→Id responses is not known. If so, it would involve proteolytic cleavage of the antibody molecule and presentation of the peptide(s) containing the Id in
the MHC groove (fig. 14a). However, other mechanisms might be considered. Conceivably, the tertiary configuration of an antibody molecule might be sufficient to present its Id to the appropriate T cell receptor molecule and activate the T cell in the absence of MHC recognition. Anti-T15 Id-specific T cells have been shown capable of binding (or being bound by) antibodies possessing the T15 Id [7]. Thus, in some cases, T cell recognition of Id can occur in the absence of antigen presenting cells and antibodies can activate T cell responses independent of MHC (fig. 14b). Another alternative for the involvement of T cells might be via IgM or IgG Fc receptors (FcR) on the surface of T cells [43]. Thus, T cells could conceivably bind to the Fc of an antibody bound to its complementary Id expressed on a B cell and be activated to function as a helper cell triggering the Id response of the B cell (fig. 14c). This might be particularly relevant to T-dependent anti-Id re-
responses when the inducing antibody (Ab1) is an IgM. IgM FcR have been described on T helper cells [44] and have been implicated functionally as being involved in T cell help in thymus-dependent antibody responses [43]. A final alternative for Fc receptor involvement would be that the inducing antibody could be bound to an antigen-presenting cell by an Fc receptor. Subsequent T cell recognition might involve side by side recognition of Id on the antibody and MHC on the presenting cells (fig. 14d).

Among these alternatives one would predict syngeneic restriction of T-dependent Id responses for the first and last alternatives but not for the other two. Previous reports have indicated a lack of syngeneic restriction for T-dependent Id responses [45, 46]. Other reports have described a lack of syngeneic restriction for T cell responses induced by a monoclonal anti-T cell antibody (expressing anti-Id) [47, 48]. The exact manner in which these T and B cells interact with one another is still at present unknown.

Activation of Id networks has been previously described in several other virus induced tumor-associated antigen systems. In the simian virus 40 (SV40) T-Ag system, BALB/c mice injected with a mixture of anti-Id reactive with mAb specific for different epitopes of SV40 T-Ag suppressed tumor formation by SV40-transformed cells [49]. In the same system, mice injected with a monoclonal anti-Id induced Ab3 antibodies, a component of which (Ab1') recognized SV40 T-Ag and shared Id determinants with Ab1 [50]. Similarly, BALB/c mice injected with a monoclonal anti-Id specific for antifeline leukemia virus (FeLV) gp70 developed an Ab3 response containing low levels of anti-FeLV antibodies [12, 51]. In the mouse mammary tumor virus (MMTV) system, an Ab1 that recognizes a shared determinant on the L1210/GZL tumor cell line and envelope gp52 of MMTV was used to generate monoclonal Ab2. Mice injected with mAb2 induced MMTV-specific antibody and tumor-specific cytotoxic lymphocytes. However, only one of the two anti-Ids examined induced protective immunity against tumor growth [52, 53].

Activation of Id networks has also been described in other (nontumor) virus systems associated with infectious disease. Mice injected with Ab2 which recognize a common Id found on antibodies specific for hepatitis B surface Ag (HBsAg) generated antibodies reactive with HBsAg in the absence of antigen [54]. The antibodies induced by injection of the anti-Id, like Ab1, expressed an interspecies Id and were able to recognize the group-specific ‘a’ determinant of HBsAg [55, 56]. Preimmunization of chimpanzees with Ab2 elicited an Ab3 response which protected the animals from infection after challenge with infectious hepatitis virus [57]. In the reovirus system, a monoclonal antibody specific for the neutralization epitope of type 3 reovirus hemagglutinin was used to generate a syngeneic monoclonal anti-Id in BALB/c mice [10]. Injection of the purified anti-Id, in the absence of viral antigen exposure, elicited an anti-anti-Id (Ab3) response [58]. This Ab3 was specific for the immunizing anti-Id and its Ab1' component was able to bind and neutralize reovirus type 3 preparations. Maternal immunization of mice with anti-Id protected neonates from challenge with a potentially lethal dose of reovirus type 3 (which causes encephalitis). The molecular mimicry of reovirus HA by anti-Id in this system was found to be related to regions of primary amino acid sequence homology observed between the two proteins [59, 60]. In both the rabies and polio-virus systems, immunization with the respective Ab2 led to production of Ab3 which contained virus-neutralizing Ab1' antibodies [11, 61]. However, no protective effect against challenge with a lethal dose of virus was
observed in these animals. A protective effect was noted however in members belonging to 9 out of 12 (75%) of the viral families studied which suggests that many of the anti-Ids generated are capable of mimicking viral epitopes or virus-induced antigens in the apparent absence of exposure to nominal antigen. These findings as well as reports of Id network activation in other viral systems are summarized in table 1.

Although these viruses belong to distinct families which differ in genetic composition, protein structure, replication, and pathology, a number of comparisons can be noted with regard to Id network activation and induction of protective immunity. In agreement with our observations of antibody-induced immune responses to the hapten DNP, and M-MuSV, activation of Id networks against other viral antigens can similarly be achieved resulting in production of Id- and antigen-specific antibodies. These antigen-specific antibodies (termed Ab1') can be frequently shown to be protective against pathogenic challenge [14, 15, 47, 52, 53, 57, 58, 88, 91, 92, 95] and provide further evidence for the role of Id network activation by antibody alone for immunotherapeutic treatment against virus-induced tumor-associated antigens and viruses associated with infectious disease.

Acknowledgments

This research was supported by Veterans Administration Medical Research funds and Grants CA-34968, CA-38008, CA-16673, CA-13148, AI-14782, and AI-07051 from the National Institutes of Health, Bethesda, Md.

References

1 Moss B: Vaccinia virus: A tool for research and vaccine development. Science. 1991;252:1662.
2 Jerne NK: Towards a network theory of the immune system. Ann Immunol (Paris) 1974;125C:373.
3 Rubinstein LJ, Yeh M, Bona CA: Idiotype-anti-idiotype network. II. Activation of silent clones by treatment at birth with idiotypes is associated with the expansion of idiotype-specific helper T cells. J Exp Med 1982;156:506.
4 Bottomly K: All idiotypes are equal, but some are more equal than others. Immunol Rev 1984;79:45.
5 Woodland R, Cantor H: Idiotype-specific T helper cells are required to induce idiotype-positive B memory cells to secrete antibody. Eur J Immunol 1978;8:600.
6 Eichmann K, Fahl I, Rajewsky K: Recognition of idiotypes in lymphocyte interactions. II. Antigen-independent cooperation between T and B lymphocytes that possess similar and complementary idiotypes. Eur J Immunol 1978;8:853.
7 Cerny J, Caulfield MJ: Stimulation of specific antibody-forming cells in antigen-primed nude mice by the adoptive transfer of syngeneic anti-idiotype T cells. J Immunol 1981;126:2262.
8 Cerny J, Cronkhiite R, Stout JT: Rapid changes in the regulatory potential of autologous anti-idiotopic T cells during an antigen-driven primary response. J Immunol 1986;136:3597.
9 Bona C, Paul WE: Cellular basis of regulation of expression of idiotype. I. T-suppressor cells specific for MOPC 460 idiotype regulate the expression of cells secreting anti-TNP antibodies bearing 460 idiotype. J Exp Med 1979;149:592.
10 Noseworthy JH, Fields BN, Dichter MA, Sobotka C, Pizer E, Perry LL, Nepom JT, Greene ME: Cell receptors for the mammalian reovirus. I. Syngeneic monoclonal anti-idiotype antibodies identifies a cell surface receptor for reovirus. J Immunol 1983;131:2533.
11 Reagan KJ, Wunner WH, Wiktor TJ, Koprowski H: Anti-idiotypic antibodies induce neutralizing antibodies to rabies virus glycoprotein. J Virol 1983;48:660.
12 Osterhaus A, Wagenaar J, Weijer K, UytdeHaag F: Idiotype networks in the immune response to feline leukemia virus. Monogr Allergy 1987;22:158.
13 Lamon EW, Powell TJ Jr, Walia AS, Lidin B, Srinivas RV, Baskin JG, Kearney JF: Monoclonal IgM antibodies that inhibit primary Moloney murine sarcoma growth. J Natl Cancer Inst 1987;78:547.
14 Powell TJ Jr, Spann R, Vakil M, Kearney JF, Lamon EW: Activation of a functional idiotype network response by monoclonal antibody specific for a virus (M-MuLV)-induced tumor antigen. J Immunol 1988;140:3266.
15 Powell TJ Jr, Spann R, Nguyen Duc M, Lamon EW: Induction of effective immunity to Moloney murine sarcoma virus using monoclonal anti-idiotype antibody as immunogen. J Immunol 1989;142:1318.
16 Baskin JG, Ryan TM, Vikil M, Kearney JF, Lamon EW: Thymus-dependent anti-idiotypic and anti-anti-idiotypic responses to a dinitrophenyl-specific monoclonal antibody. J Immunol 1990;145:202.

17 Baskin JG, Vikil M, Kearney JF, Ryan T, Lamon EW: Thymus-dependent network responses to a monoclonal cross-reactive anti-idiotypic antibody. J Immunol 1991;147:1849.

18 Moloney JB: A virus-induced rhabdomyosarcoma of mice. Natl Cancer Inst Monogr 1966;22:139.

19 Hartley JW, Rowe WP: Production of altered cell foci in tissue culture by defective Moloney sarcoma virus particles. Proc Natl Acad Sci USA 1966;55:780.

20 Fefer A, McCoy JL, Glyn J: Induction and regression of primary Moloney sarcoma virus-induced tumors in mice. Cancer Res 1967;27:1626.

21 Lamon EW, Skurzak HM, Klein E: The lymphocyte response to a primary viral neoplasm (MSV) through its entire course in BALB/c mice. Int J Cancer 1972;10:581.

22 Lamon EW, Klein E, Andersson B, Feny6 EM, Skurzak HM: The humoral antibody response to a primary viral neoplasm (MSV) through its entire course in BALB/c mice. Int J Cancer 1973;12:637.

23 Lamon EW, Wigzell H, Klein E, Andersson B, Skurzak HM: The lymphocyte response to primary Moloney sarcoma virus tumors in BALB/c mice. Definition of the active subpopulations at different times after infection. J Exp Med 1973;137:1472.

24 Lamon EW, Skurzak HM, Andersson B, Whitten HD, Klein E: Antibody-dependent lymphocyte cytotoxicity in the murine sarcoma virus system: Activity of IgM and IgG with specificity for MLV determined antigen(s). J Immunol 1975;114:1171.

25 Lamon EW, Whitten HD, Skurzak HM, Anderson B, Lidin B: IgM antibody-dependent cell-mediated cytotoxicity in the Moloney sarcoma virus system: The involvement of T and B lymphocytes as effector cells. J Immunol 1975;115:1288.

26 Lamon EW, Shaw MW, Goodson S, Lidin B, Wallis AS, Fusion EW: Anti-body-dependent cell-mediated cytotoxicity in the Moloney sarcoma virus system: Differential activity of IgG and IgM with different subpopulations of lymphocytes. J Exp Med 1977;145:302.

27 Chuat JC, Berman L, Gunvén P, Klein E: Studies on murine sarcoma virus: Antigenic characterization of murine sarcoma virus induced tumor cells. Int J Cancer 1969;4:465.

28 Stephenson JR, Aaronson SA: Antibody properties of murine sarcoma virus-transformed BALB/3T3 nonproducer cells. J Exp Med 1972;147:503.

29 Strouk V, Graudner G, Feny6 EM, Lamon E, Skurzak H, Klein G: Lack of distinctive surface antigen on cells transformed by murine sarcoma virus. J Exp Med 1972;136:344.

30 Schwartzbert P, Colicelli J, Goff SP: Detection of a mutant of Moloney murine leukemia virus which lacks glycosylated gag protein are replication competent. J Virol 1983;46:538.

31 Vakil M, Sauter H, Paige C, Kearney JF: In vivo suppression of perinatal multispecific B cells results in a distortion of the adult B cell repertoire. Eur J Immunol 1986;16:1139.

32 Dzierzak EA, Rosenstein RW, Jancey CA Jr: Expression of an idio-type (id-460) during in vivo anti-dinitrophenyl antibody responses. II. Transient idiotypic dominance. J Exp Med 1981;154:1432.

33 Zeldis JB, Riblet R, Konigberg WH, Richards FF, Rosenstein RW: The location and expression of idiotypic determinants in the immunoglobulin variable region III. Expression of the protein 315 and 460 idiotypic determinants in mouse anti-DNP antibodies. Mol Immunol 1979;16:657.

34 Brodeur PH, Riblet R: The immunoglobulin heavy chain variable region (Igh-V) locus in the mouse. I. One hundred Igh-V genes comprise seven families of homologous genes. Eur J Immunol 1984;14:922.

35 Marion TN, Dzierzak EA, Lee H-S, Adams RL, Janeway CA Jr: Nondinitrophenyl-binding immunoglobulin that bears a dominant idiotype (Id460) associated with antidinitrophenyl antibody is specific for an antigen on Pasteurella pneumotropica. J Exp Med 1984;159:221.

36 Nisonoff A, Lamoyi E: Hypothesis: Implications of the presence of an internal image of the antigen in anti-idiotypic antibodies: Possible application to vaccine production. Clin Immunol Immunopathol 1981;21:397.

37 Jerne NK, Roland J, Cazenave P-A: Recurrent idiotopes and internal images. EMBO 1982;1:343.

38 Bona CA, Kohler H: Anti-idiotypic antibodies and internal images; in Venter JC, Fraser CM, Lindstrom J (eds): Monoclonal and Anti-Idiotypic Antibodies. Probes for Receptor Structure and Function. New York, Liss, 1984, vol 4, pp 141–150.

39 Huang J-H, Ward RE, Kohler H: Idiotypic antigens (Ab2a and Ab2b) can induce in vitro B cell proliferation and antibody production. J Immunol 1986;137:770.

40 Schick MR, Dreesman GR, Kenney RC: Induction of an anti-hepatitis B surface antigen response in mice by noninternal image (Ab2a) anti-idiotypic antibodies. J Immunol 1987;138:3419.

41 Huang J-Y, Ward RE, Kohler H: Biological mimicry of antigenic stimulation: Analysis of the in vivo antibody responses induced by monoclonal anti-idiotypic antibodies. Immunology 1988;63:1.

42 Kohler H, Kieber-Emmons T, Srini-vasan S, Kaveri S, Morrow WJ, Müller S, Kang CY, Raychaudhuri S: Short analytical review: Revised immune network concepts. Clin Immunol Immunopathol 1989;52:104.

43 Andersson B, Skoglund A-C, Rönnholm M, Lindsten T, Lamon EW, Collison EW, Wallis AS: Functional aspects of IgM and IgG Fc receptors on murine T lymphocytes. Immunol Rev 1981;56:5.

44 Moretta L, Webb SR, Grossi CE, Lydyard PM, Cooper MD: Functional analysis of two human T-cell subpopulations: Help and suppression of B-cell responses by T cells bearing receptors for IgM or IgG. J Exp Med 1977;146:184.
73 Paque RE, Miller R: Modulation of murine coxsackievirus-induced myocarditis utilizing anti-idiotypes. Viral Immunol 1988;1:207.
74 Paque RE, Miller R: Monoclonal anti-idiotypic antibodies regulate the expression of virus-induced murine myocarditis. Infect Immun 1989;57:2864.
75 McClintock PR, Prabhakar BS, Notkins AL: Anti-idiotypic antibodies to monoclonal antibodies that neutralize coxsackievirus B4 do not recognize viral receptors. Virology 1986:150:352.
76 Anders EM, Kapaklis-Deliyannis GP, White DO: Induction of immune response to influenza virus with anti-idiotypic antibodies. J Virol 1989;63:2738.
77 Finberg RW, Ertl HCJ: Use of T cell-specific anti-idiotypes to immunize against viral infections. Immunol Rev 1986;90:129.
78 Ertl HCJ, McCarthy E, Homans E, Finberg RW: Induction of antiglial immune response by anti-idiotypic antibody directed against a Sendai virus-specific murine T-helper-cell clone: in Dresman GR, Bronson JG, Kennedy RC (eds): High-Technology Route to Virus Vaccines. Proceedings of the First Annual Southwest Foundation for Biomedical Research. International Symposium, Houston, 1984, p 125.
79 Tanaka M, Sasaki N, Seto A: Induction of antibodies against Newcastle disease virus with syngeneic anti-idiotypic antibodies in mice. Microbial Immunol. 1986;30:323.
80 Palomo C, Albar JP, Garcia-Barreno B, Melero JA: Induction of a neutralizing immune response to human respiratory syncytial virus with anti-idiotypic antibodies. J Virol 1990;64:4199.
81 Keay S, Rasmussen L, Merigan TC: Syngeneic monoclonal anti-idiotypic antibodies that bear the internal image of a human cytomegalovirus neutralization epitope. J Immunol 1988;140:944.
82 Gürün MF, Ben-Porat T, Naisonoff A: Induction of antibodies to pseudoviruses by immunization with anti-idiotypic antibodies. Ann Inst Pasteur 1988;139:677.
83 Kennedy RC, Adler-Storthz K, Burns JW Sr, Henkel RD, Dreesman GR: Anti-idiotypic modulation of herpes simplex virus infection leading to increased pathogenicity. J Virol 1984;50:951.
84 Lathey JL, Rouse BT, Wiley DE, Courtney RJ: Production and characterization of an anti-idiotypic antibody specific for a monoclonal antibody to glycoprotein D of herpes simplex virus. Immunology 1986;57:29.
85 Nath A, Slagle B, Wolinsky JS: Anti-idiotypic antibodies to rubella virus. Arch Virol 1989;107:159.
86 Roehrig JT, Hunt AR, Mathews JH: Identification of anti-idiotypic antibodies that mimic the neutralization site of Venezuelan equine encephalomyelitis virus; in Dresman GR, Bronson JG, Kennedy RC (eds): High-Technology Route to Virus Vaccines. Proceedings of the First Annual Southwest Foundation for Biomedical Research. International Symposium, Houston, 1984, p 142.
87 Gnahnakar SA, Cecilia D, Kutubuddin M, Goverdhan MK, Dandawate CN, Banerjee SC, Ghosh SN: Characterization of & induction of immune response to anti-idiotypic antibodies for JE virus. Indian J Med Res 1991;93:131.
88 Shearer MH, Bright RK, Kennedy RC: Comparison of humoral immune responses and tumor immunity in mice immunized with recombinant SV40 large tumor antigen and a monoclonal anti-idiotypic. Cancer Res 1993;53:5734.
89 Agostini HT, Gerstenecker B, Haessler C, Braun DG, Brandser G, Hess RD: Monospecific polyclonal anti-anti-idiotypic antibodies to the carboxyterminal undecapeptide of the SV40 large tumour antigen. Scand J Immunol 1995;41:226.
90 Tackaberry ES, Hamel J, Larose Y, Brodeur BR: Anti-idiotypic mimicry of a neutralizing epitope on the glycoprotein B complex of human cytomegalovirus. J Virol 1993;67:6815.
91 Tsuda T, Onodera T, Sugimura T, Murakami Y: Induction of protective immunity and neutralizing antibodies to pseudoviruses by immunization of anti-idiotypic antibodies. Arch Virol 1983;119:291.
92 Oosterlaken TAM, Harmens M, Hjghmeer-Singh SS, Eetijin GL, Kraaijveeld CA, Snippe H: A protective monoclonal anti-idiotypic vaccine to lethal Semliki forest virus infection in BALB/c mice. J Virol 1991;65:98.
93 Hartharan K, Srikumaran S, Moxley RA, Osorio FA, Morales AA: Induction of neutralizing antibodies to transmissible gastroenteritis virus by anti-idiotypic antibodies. Viral Immunol 1989;2:133.
94 Sune C, Smerdou C, Anton IM, Abril P, Plana J, Enjuanes L: A conserved coronavirus epitope, critical in virus neutralization, mimicked by internal-image monoclonal anti-idiotypic antibodies. J Virol 1991;65:6979.
95 Lamarre A, Lecomte J, Talbot PJ: Anti-idiotypic vaccination against murine coronavirus infection. J Immunol 1990;147:4256.
96 Wiley JA, Hamel J, Brodeur BR: Monoclonal anti-idiotypic induce neutralizing antibodies to enterovirus 70 conformational epitopes. J Virol 1992;66:5744.